Oral Relistor Approval the First of Many Progenics Pharmaceuticals (PGNX) Drivers - Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Brean Capital Sees 'Significant Uptake' for Progenics' (PGNX) Oral Relistor
July 20, 2016 10:22 AM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and $14 price target on Progenics Pharmaceuticals (NASDAQ: PGNX) after the company and Valeant announced FDA approval of oral Relistor for the treatment of OIC in chronic non-cancer pain patients.
Aschoff commented, "Even with direct competitor Movantik on... More
Progenics Pharma (PGNX) Surges Over 20% as FDA Approval Oral RELISTOR
July 20, 2016 8:10 AM EDTProgenics Pharma (NASDAQ: PGNX) is ramping 21% in pre-open trade Wednesday after the company and Valeant Pharmaceuticals (NYSE: VRX) announced that the FDA has approved RELISTOR Tablets for the treatment of opioid-induced constipation (OIC) in adults with chronic... More
BTIG Positive on Progenics Pharma (PGNX) Following FDA Approval of RELISTOR as OIC Treatment (VRX)
July 20, 2016 7:57 AM EDTBTIG affirms Progenics Pharmaceuticals (Nasdaq: PGNX) at Buy with a price target of $9 after Progenics and Valeant Pharma (NYSE: VRX)... More
Progenics (PGNX) volatility elevated into FDA approval of constipation treatment
July 20, 2016 5:43 AM EDTProgenics Pharma (NASDAQ: PGNX) August call option implied volatility is at 177, September is at 133; compared to its 52-week range of 57 to 173 into Valeant Pharmaceuticals International (VALEANT) and Progenics Pharmaceuticals announced that the FDA has approved RELISTOR Tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.
... MoreValeant Pharma (VRX), Progenics Pharmaceuticals (PGNX) Granted FDA Approval for RELISTOR
July 19, 2016 6:06 PM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the U.S. Food and Drug Administration has approved RELISTOR® (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. Valeant expects to commence sales of RELISTOR Tablets in the U.S. in the third quarter of 2016.
"Opioid-induced constipation represents a long-lasting and potentially debilitating side effect of opioid... More
